Literature DB >> 15872266

Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus.

Stephanie M Perkins1, David L Webb, Shauna A Torrance, Chadi El Saleeby, Lisa M Harrison, Jody A Aitken, Anami Patel, John P DeVincenzo.   

Abstract

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory infection of children. Understanding RSV pathogenesis and evaluating interventions requires quantitative RSV testing. Previous studies have used the plaque assay technique. Real-time reverse transcriptase PCR (RTrtPCR) offers possible greater sensitivity, stability after freeze/thaw, and lower cost, thus facilitating multicenter studies. We developed RTrtPCR assays based upon the RSV N and F genes. The N-gene assay detected greater RSV quantity and was further evaluated. Standard curves utilized both extractions from RSV culture supernatants of known quantity and cloned purified copies of the target DNA. In vitro, the ratio of RSV subgroup A (RSV-A) genome copies to PFU was 153:1. A total of 462 samples collected quantitatively from 259 children were analyzed in duplicate by RTrtPCR. Results were compared with those of RSV plaque assays performed on fresh aliquots from the same children. Duplicate RTrtPCR results were highly correlated (r2 = 0.9964). The mean viral load from nasal washes obtained on the first study day was 5.75 +/- standard error of the mean 0.09 log PFU equivalents (PFUe)/ml. Viral load by RTrtPCR correlated with plaque assay results (r2 = 0.158; P < 0.0001). Within individuals, upper and lower respiratory tract secretions contained similar viral concentrations. RSV-A-infected children had 1.17 log PFUe higher viral loads than did those with RSV-B (P < 0.0001). RSV quantification by RTrtPCR of the N gene is precise and has significant, though limited, correlation with quantitative culture. The utility of the RTrtPCR quantification technique for clinical studies would be solidified after its correlation with RSV disease severity is established.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15872266      PMCID: PMC1153767          DOI: 10.1128/JCM.43.5.2356-2362.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Bronchiolitis-associated hospitalizations among US children, 1980-1996.

Authors:  D K Shay; R C Holman; R D Newman; L L Liu; J W Stout; L J Anderson
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.

Authors:  T G Boyce; B G Mellen; E F Mitchel; P F Wright; M R Griffin
Journal:  J Pediatr       Date:  2000-12       Impact factor: 4.406

3.  Severity of respiratory syncytial virus infection is related to virus strain.

Authors:  E E Walsh; K M McConnochie; C E Long; C B Hall
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

4.  Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.

Authors:  E E Wang; B J Law; F D Boucher; D Stephens; J L Robinson; S Dobson; J M Langley; J McDonald; N E MacDonald; I Mitchell
Journal:  J Pediatr       Date:  1996-09       Impact factor: 4.406

5.  Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load.

Authors:  John P Devincenzo
Journal:  Pediatr Res       Date:  2004-10-06       Impact factor: 3.756

6.  Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults.

Authors:  J A Englund; P A Piedra; A Jewell; K Patel; B B Baxter; E Whimbey
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

7.  Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.

Authors:  E E Wang; B J Law; D Stephens
Journal:  J Pediatr       Date:  1995-02       Impact factor: 4.406

8.  Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.

Authors:  R Malley; J DeVincenzo; O Ramilo; P H Dennehy; H C Meissner; W C Gruber; P J Sanchez; H Jafri; J Balsley; D Carlin; S Buckingham; L Vernacchio; D M Ambrosino
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

9.  [Prevalence and clinical aspects of A and B subgroups of respiratory syncytial virus infection. Observation of 8 consecutive epidemics between 1982 and 1990].

Authors:  J Brouard; F Freymuth; S Constantini; J Petitjean; G de Schrevel; J F Duhamel
Journal:  Arch Fr Pediatr       Date:  1993-10

10.  A single-season epidemic with respiratory syncytial virus subgroup B2 during 10 epidemic years, 1978 to 1988.

Authors:  M A Mufson; B Akerlind-Stopner; C Orvell; R B Belshe; E Norrby
Journal:  J Clin Microbiol       Date:  1991-01       Impact factor: 5.948

View more
  55 in total

1.  Deep sequencing of RSV from an adult challenge study and from naturally infected infants reveals heterogeneous diversification dynamics.

Authors:  Jessica W Lau; Young-In Kim; Ryan Murphy; Ruchi Newman; Xiao Yang; Michael Zody; John DeVincenzo; Yonatan H Grad
Journal:  Virology       Date:  2017-08-03       Impact factor: 3.616

2.  Methods for monitoring dynamics of pulmonary RSV replication by viral culture and by real-time reverse transcription-PCR in vivo: Detection of abortive viral replication.

Authors:  Marina S Boukhvalova; Kevin C Yim; Gregory A Prince; Jorge C G Blanco
Journal:  Curr Protoc Cell Biol       Date:  2010-03

3.  Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.

Authors:  Lindsay Broadbent; Hong Guo Parke; Lyndsey J Ferguson; Andrena Millar; Michael D Shields; Laurent Detalle; Ultan F Power
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

4.  Elevated Levels of Type 2 Respiratory Innate Lymphoid Cells in Human Infants with Severe Respiratory Syncytial Virus Bronchiolitis.

Authors:  Luan D Vu; David Siefker; Tamekia L Jones; Dahui You; Ryleigh Taylor; John DeVincenzo; Stephania A Cormier
Journal:  Am J Respir Crit Care Med       Date:  2019-12-01       Impact factor: 21.405

5.  Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children.

Authors:  Chadi M El Saleeby; Andy J Bush; Lisa M Harrison; Jody A Aitken; John P Devincenzo
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

6.  Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

Authors:  John P DeVincenzo; Tom Wilkinson; Akshay Vaishnaw; Jeff Cehelsky; Rachel Meyers; Saraswathy Nochur; Lisa Harrison; Patricia Meeking; Alex Mann; Elizabeth Moane; John Oxford; Rajat Pareek; Ryves Moore; Ed Walsh; Robert Studholme; Preston Dorsett; Rene Alvarez; Robert Lambkin-Williams
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

Review 7.  Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.

Authors:  John H Beigel; Hannah H Nam; Peter L Adams; Amy Krafft; William L Ince; Samer S El-Kamary; Amy C Sims
Journal:  Antiviral Res       Date:  2019-04-08       Impact factor: 5.970

8.  Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants.

Authors:  Monica E Brint; Joshua M Hughes; Aditya Shah; Chelsea R Miller; Lisa G Harrison; Elizabeth A Meals; Jacqueline Blanch; Charlotte R Thompson; Stephania A Cormier; John P DeVincenzo
Journal:  Pediatr Res       Date:  2017-08-09       Impact factor: 3.756

9.  Respiratory syncytial virus persistence in the lungs correlates with airway hyperreactivity in the mouse model.

Authors:  Dora Estripeaut; Juan Pablo Torres; Cynthia S Somers; Claudia Tagliabue; Shama Khokhar; Vijay G Bhoj; Steve M Grube; Aneta Wozniakowski; Ana M Gomez; Octavio Ramilo; Hasan S Jafri; Asuncion Mejias
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

10.  Duration of shedding of respiratory syncytial virus in a community study of Kenyan children.

Authors:  Emelda A Okiro; Lisa J White; Mwanajuma Ngama; Patricia A Cane; Graham F Medley; D James Nokes
Journal:  BMC Infect Dis       Date:  2010-01-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.